No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ABBV241227P167500
- 0.13
- -0.47-78.33%
15min DelayClose Dec 20 16:00 ET
0.45High0.10Low
0.45Open0.60Pre Close10 Volume41 Open Interest167.50Strike Price169.00Turnover27.85%IV4.68%PremiumDec 27, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type-0.0565Delta0.0213Gamma949.08Leverage Ratio-0.0623Theta-0.0011Rho-53.67Eff Leverage0.0217Vega
Intraday
- 5D
- Daily
News
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
AbbVie Insiders Sell US$56m Of Stock, Possibly Signalling Caution
AbbVie Hits 4-week Low
AbbVie's Atogepant And OnabotulinumtoxinA Receive Strong Recommendations In The Newly Updated Canadian Headache Society Migraine Prevention Guideline; A Strong Recommendation Was Issued When An Intervention Was Deemed Suitable For The Majority Of...
Express News | Abbvie's Atogepant and Onabotulinumtoxina Receive Strong Recommendations in the Newly Updated Canadian Headache Society (Chs) Migraine Prevention Guideline